

## References

I-213

1. Zulresso™ (brexanolone) injection, for intravenous use. [package insert]. Sage Therapeutics. Cambridge, MA. 06/2019.
2. Hayes, Inc. Hayes Prognosis Overview. Zulresso (Brexanolone) for Postpartum Depression. Landsdale, PA: Hayes, Inc.; March 2019.
3. Kanes S, Colquhoun H, Doherty J, et. al. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. *Hum Psychopharmacol.* 2017;32(2):e2576.
4. Kanes S, Colquhoun H, Gunduz-Bruce H, et. al. Brexanolone (SAGE-547 injection) in Post-Partum Depression: a Randomised Controlled Trial. *Lancet.* 2017;390:480-489.
5. Meltzer-Brody S, Colquhoun H, Riesenbergr R, et. al. Brexanolone Injection in Post-Partum Depression: Two Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trials. *Lancet.*2018;392:1058-1070.
6. Curry SJ, Krist AH, Owens DK, et al. Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. *JAMA.* Feb 12 2019; 321(6): 580-587.
7. Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Third Edition).  
[https://psychiatryonline.org/pb/assets/raw/sitewide/practice\\_guidelines/guidelines/mdd.pdf](https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf). Accessed February 20, 2019
8. FDA Presentations for the November 2, 2018 Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.  
<https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM629509.pdf>. Accessed February 19, 2020
9. Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. *Lancet.* Jul 29 2017; 390(10093): 480-489.
10. Molyneaux E, Telesia LA, Henshaw C, et al. Antidepressants for preventing postnatal depression. *Cochrane Database Syst Rev.* Apr 18 2018; 4: CD004363.
11. FDA Briefing Information for the November 2, 2018 Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.  
<https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs>

- /PsychopharmacologicDrugsAdvisoryCommittee/ucm624642.htm. Accessed February 19, 2020
12. Sage Briefing Information for the November 2, 2018 Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee.  
<https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM624646.pdf>. Accessed February 19, 2020.
  13. Ko JY, Rockhill KM, Tong VT, et al. Trends in Postpartum Depressive Symptoms - 27 States, 2004, 2008, and 2012. *MMWR Morb Mortal Wkly Rep.* Feb 17 2017; 66(6): 153-158.
  14. Meltzer-Brody S, Colquhoun H, Riesenbergr R, et al. Brexanolone injection in post-partum depression: Two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet (London, England)*. 2018;392(10152):1058-1070.
  15. Kaner S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (sage-547 injection) in post-partum depression: A randomised controlled trial. *Lancet (London, England)*. 2017;390(10093):480-489.
  16. Zulresso™ (brexanolone) injection, for intravenous use. [package insert]. Sage Therapeutics.
  17. Cambridge, MA. 06/2019
  18. Leader LD, O'Connell M, Vandenberg A. Brexanolone for postpartum depression: Clinical evidence and practical considerations. *Pharmacotherapy*. 2019;39(11):1105-1112.
  19. Scarff JR. Use of brexanolone for postpartum depression. *Innovations in Clinical Neuroscience*. 2019;16(11/12):32-35.
  20. Hayes, Inc. Evidence analysis research brief. Brexanolone (Zulresso) for treatment of postpartum depression. Landsdale, PA: Hayes, Inc.; October 27, 2020.
  21. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. Brexanolone.
  22. Micromedex DrugDex Compendium®. 2020. Brexanolone (Zulresso).